Table 6.
CREDO—Primary Efficacy Analysis (1 Year) Stratified by PPI Type Using Various Definitions for PPI Treatment
| Subgroup | Clopidogrel, n (%) | Placebo, n (%) | Estimated Unadjusted HR (95% CI) | P Value for Interaction | |
|---|---|---|---|---|---|
| Baseline PPI use | |||||
| Any PPI | No (n=1742) | 66 (7.6) | 91 (10.5) | 0.71 (0.52 to 0.98) | 0.682 |
| Yes (n=374) | 23 (12.8) | 31 (15.9) | 0.82 (0.48 to 1.40) | ||
| Omeprazole | No (n=1961) | 80 (8.2) | 112 (11.4) | 0.71 (0.54 to 0.95) | 0.602 |
| Yes (n=155) | 9 (11.7) | 10 (12.8) | 0.93 (0.38 to 2.28) | ||
| Lansoprazole | No (n=1898) | 74 (7.8) | 102 (10.7) | 0.72 (0.53 to 0.97) | 0.721 |
| Yes (n=218) | 15 (14.4) | 20 (17.5) | 0.82 (0.42 to 1.61) | ||
| Pantoprazole | No (n=2101) | 88 (8.4) | 118 (11.2) | 0.75 (0.57 to 0.99) | 0.202 |
| Yes (n=15) | 1 (12.5) | 4 (57.1) | 0.13 (0.01 to 1.18) | ||
| Rabeprazole | No (n=2107) | 89 (8.5) | 122 (11.5) | 0.73 (0.55 to 0.96) | N/A |
| Yes (n=9) | 0 | 0 | N/A | ||
| Any PPI use | |||||
| Any PPI | No (n=1490) | 53 (7.0) | 74 (10.0) | 0.69 (0.49 to 0.99) | 0.551 |
| Yes (n=626) | 36 (12.0) | 48 (14.8) | 0.82 (0.53 to 1.26) | ||
| Omeprazole | No (n=1826) | 72 (8.0) | 103 (11.2) | 0.71 (0.52 to 0.95) | 0.578 |
| Yes (n=290) | 17 (11.5) | 19 (13.4) | 0.86 (0.45 to 1.66) | ||
| Lansoprazole | No (n=1754) | 63 (7.2) | 91 (10.4) | 0.68 (0.49 to 0.94) | 0.348 |
| Yes (n=362) | 26 (14.9) | 31 (16.6) | 0.91 (0.54 to 1.54) | ||
| Pantoprazole | No (n=2054) | 85 (8.3) | 113 (10.9) | 0.76 (0.57 to 1.00) | 0.271 |
| Yes (n=62) | 4 (12.5) | 9 (30.0) | 0.38 (0.12 to 1.25) | ||
| Rabeprazole | No (n=2081) | 89 (8.6) | 122 (11.7) | 0.72 (0.55 to 0.95) | N/A |
| Yes (n=35) | 0 | 0 | N/A | ||
CREDO indicates Clopidogrel for Reduction of Events During Observation; PPI, proton pump inhibitor; HR, hazard ratio; N/A, not available.